Late-stage cancer diagnosis drives soaring medical costs and lower survival rates
A new study using Medicare data shows that patients diagnosed with advanced cancer incur average medical expenses of nearly $122,000 in their final year, while early detection can dramatically improve survival and reduce costs.
A joint analysis by the National Cancer Institute and the American Cancer Society examined Medicare claims for seniors 66 and older, revealing that cancer-related medical spending totals roughly $122,000 in the last year of life, especially when the disease has already metastasized. The study highlights breast cancer as a case where early detection yields a five-year relative survival rate of 100%, compared with just 33.8% after distant spread, underscoring the life-saving and cost-saving potential of timely screening.
In 2020, the United States spent $29.8 billion on breast cancer care, the highest among all cancers, with prescription drug costs ranging from about $700 for early-stage patients to $25,000 for those with advanced disease. Modeling by the CDC suggests biennial mammograms for women 50-74 cut mortality by 26% and reduce late-stage diagnoses by 29%. While appropriate testing should match age and risk, the authors caution that insurance hurdles, such as prior-authorization requirements for high-risk MRI screening, may delay essential care and increase overall expenditures.
Why it matters
Early cancer detection can save lives and lower costly advanced-stage treatments.
In this story
